Evidence map›Paper›PMID 42504297›Full record

ArticleImmunoTargets and therapy2026

Increased Expression of HLA-DR and CD69 on Peripheral CD4

Ana Tomás, José Maximino, Hugo Nunes, Rute Salvador, Rafael Luís, Cheila Brito, Diana P Saraiva, Emanuel Gouveia, Carolina Pereira, Filipe Gonçalves and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ana TomásUnidade de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.ORCID 0000-0003-4710-2605
José MaximinoUnidade de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.
Hugo NunesServiço de Oncologia Médica, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.
Rute SalvadoriNOVA4Health, NOVA Medical School, Universidade NOVA de Lisboa, Lisboa, Portugal.
Rafael LuísUnidade de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.ORCID 0000-0002-8305-1625
Cheila BritoUnidade de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.
Diana P SaraivaiNOVA4Health, NOVA Medical School, Universidade NOVA de Lisboa, Lisboa, Portugal.
Emanuel GouveiaServiço de Oncologia Médica, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.
Carolina PereiraServiço de Oncologia Médica, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.
Filipe GonçalvesServiço de Imunohemoterapia, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.ORCID 0000-0003-0582-137X
Victor FarrichaServiço de Cirurgia, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.
Elisabete Lopez CarvalhoUnidade de Investigação Clínica, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.
Cecília MouraServiço de Dermatologia, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.
Maria José PassosServiço de Oncologia Médica, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.
Sofia Cristóvão-FerreiraServiço de Oncologia Médica, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.
Patrícia M PereiraServiço de Oncologia Médica, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.
Maria Guadalupe CabraliNOVA4Health, NOVA Medical School, Universidade NOVA de Lisboa, Lisboa, Portugal.
Marta PojoUnidade de Investigação em Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cutaneous melanoma (CM) is an aggressive skin cancer with rising incidence, representing a growing public health concern. Despite the remarkable success of immune-checkpoint inhibitors (ICIs) in the management of advanced disease, mortality remains high due to therapy resistance. Identifying reliable prognostic and predictive biomarkers is therefore essential to improve patient stratification, optimize treatment selection, and minimize unnecessary toxicity. Methods: We comprehensively profiled the circulating immune landscape of 54 treatment-naïve CM patients by integrating flow cytometry immunophenotyping with clinicopathological data, and performed tumor gene expression analysis in a subset of 26 patients. Results: Elevated HLA-DR and CD69 expression on circulating CD4 Conclusion: These findings highlight systemic CD4

Indexed as

CD4+ T cell activationcutaneous melanomaimmune-checkpoint inhibitorsimmunotherapypredictive biomarkersprognostic biomarkers

Identifiers

PMID42504297
PMCPMC13401888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.